PT2977

Merck wins priority review for rare carcinoma drug belzutifan, the centerpiece of $1B+ Peloton buyout
Endpoints
Tue, 03/16/21 - 10:54 am
Merck
Peloton Therapeutics
belzutifan
M&A
PT2977
renal cell carcinoma
priority review
FDA
Peloton Therapeutics Initiates Phase II Trials of Treatment for Rare Kidney Cancer
CP Wire
Wed, 06/6/18 - 09:42 am
Peloton Therapeutics
renal cell carcinoma
PT2977
Peloton Therapeutics Initiates Phase II Trials of Treatment for Rare Kidney Cancer
Wed, 06/6/18 - 09:33 am
Peloton Therapeutics
renal cell carcinoma
PT2977